Name: ConvaTec ActiveLife One-Piece Convex Pre-Cut Transparent Urostomy Pouch With Durahesive Skin Barrier,200/Case,125365
Brand: CONVATEC
SKU: 525-126427
Price: 1799.99 USD
Availability: InStock

ConvaTec ActiveLife One-Piece Convex Pre-Cut Transparent Urostomy Pouch With Durahesive Skin Barrier,200/Case,125365 - 525-126427

By CONVATEC

$1,799.99

(791 Reviews)

Model

525-126427

Store

Health Products For You

Manufacturer

CONVATEC

Detail

ConvaTec ActiveLife One-Piece Convex Pre-Cut Transparent Urostomy Pouch With Durahesive Skin Barrier combines the skin barrier and the pouch into one simple, easy-to-manage system. Durable comfort panel is designed to be odour-proof and quiet to maintain discretion. Tap at bottom allows for easy draining of urine.

Category

Ostomy

Pregnant patients with systemic sclerosis demonstrate a higher risk for adverse pregnancy outcomes, including preterm delivery, than those with lupus and healthy controls, according to data published in Arthritis Research & Therapy. Until now, even though the overall obstetric result reported in the literature was good, there is no uniformity among the different studies, with discordant findings of different adverse pregnancy outcomes, Gerard Espinosa, MD, PhD, of the Hospital Cl�nic de Barcelona, told Healio. To examine the prevalence of adverse pregnancy outcomes in pregnant ...

>Read More

Primary care clinics that implemented an outreach intervention had a greater proportion of patients who converted from current to former smokers than clinics without the intervention, according to findings published in Preventive Medicine. A comprehensive, health system-wide approach to smoking treatment in adult primary care may markedly improve smoking cessation treatment delivery and success, Danielle E. McCarthy, MS, PhD, the associate director of research at the University of Wisconsin Center for Tobacco Research and Intervention, and colleagues wrote. This program ...

>Read More

The FDA has approved an investigational new drug application from Ceruvia Lifesciences to conduct a phase 2 clinical trial to determine the safety and efficacy of synthetic psilocybin for the treatment of obsessive-compulsive disorder. With positive preliminary results from a Ceruvia-funded pilot phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA approval to begin our phase 2 clinical trial to examine the efficacy and safety of psilocybin in treating OCD, Ceruvia CEO Carey Turnbull said in a company press release. With few effective ...

>Read More

CHARLOTTE, N.C. - Results from the Wake Up America poll showed that practitioners do not often ask patients about insomnia, and patients may be hesitant to discuss it, Andrew Krystal, MD, MS, said at the SLEEP meeting. The most important thing we got out of this survey was a great fundamental foundation upon which to be able to develop new surveys and identify the important questions we need to ask to help us optimally understand the process by which people seek care and get treated and figure out ways to improve that process, he said. ...

>Read More

CHICAGO -- Just 18% of women experiencing homelessness who were eligible underwent a mammography over a 5-year period, according to research presented at ASCO Annual Meeting. In contrast, for women not experiencing homelessness, the rate was 32%, so almost double, Chirag S. Shah, MD, a staff member in the department of radiation oncology and co-director of the Comprehensive Breast Program at Cleveland Clinic, told Healio about results from the poster. Researchers identified women experiencing homelessness who presented for care in a hospital system starting January 2014 ...

>Read More

Molecular signature response classifier-assisted rheumatoid arthritis treatment selection may improve real-world results in patients with rheumatoid arthritis, according to data published in Expert Opinion on Biological Therapy. This study reports the second interim analysis of the [Accelerate Information of Molecular Signatures (AIMS)] real-world study evaluating the clinical utility of the [molecular signature response classifier (MSRC)] test, Vibeke Strand, MD, adjunct clinical professor at the division of immunology and rheumatology at the Stanford University School of ...

>Read More

Recurrent episodes of childhood bronchitis appear to be associated with increased risk for lung disease later in life, researchers reported in BMJ Open Respiratory Research. This is the first very long-term prospective study that has examined the relationship between childhood bronchitis severity with adult lung health outcomes, Jennifer L. Perret, MD, respiratory and sleep epidemiologist at the Centre for Epidemiology and Biostatistics at the University of Melbourne, said in a related press release. We have seen already that children with protracted bacterial bronchitis ...

>Read More

Product Details for 525-126427